1例三联治疗难治性子宫内膜癌多发肺转移病案报道及文献复习  

The Triple-Combination Therapy of Refrac-tory Metastatic Endometrial Carcinoma: A Case Report and Literature Review

作　　者：刘昕 王天昶 穆允凤 刘鹏 王锋刚 刘秋芳 

机构地区：[1]西安医学院研究生院,陕西 西安 [2]陕西省肿瘤医院放疗病院,陕西 西安 [3]陕西省肿瘤医院妇瘤病院,陕西 西安 [4]西安交通大学第一附属医院,MED-X再生与重建研究所,陕西 西安

出　　处：《临床医学进展》2023年第7期11340-11347,共8页Advances in Clinical Medicine

摘　　要：目的:晚期子宫内膜癌一线治疗的疗效普遍较低,目前尚无标准的二线治疗方案。本研究旨在探讨化疗失败后的子宫内膜癌多发肺转移患者应用三联疗法的临床意义及抗肿瘤机制。方法:给予患者立体定向消融放疗、粒细胞–巨噬细胞集落刺激因子(granulocyte-macrophage colony stimulating factor, GM- CSF)联合替雷利珠单抗的三联治疗。一共11个肺转移灶中的8个同时接受了50 Gy的SABR治疗。结果:治疗结束后6个月疗效评价为部分缓解。24个月后疗效评定为病情稳定。无进展生存期达24个月。本病例疗效显著,是首次将三联疗法应用在子宫内膜癌的病例报道。结论:基于这一病例,我们认为三联疗法是治疗子宫内膜癌肺转移患者的一种非常有潜力的二线治疗方法,值得进一步探索。Purpose: The therapeutic efficacy of first-line treatment for advanced endometrial carcinoma (EC) is generally reported to be low, and currently, there are no standard second-line treatment options. In this study, we aimed to explore the clinical significance and antitumor mechanism of tri-ple-combination therapy administered to a patient with chemotherapy-resistant, multiple lung metastases EC. Methods: The patient had 11 pulmonary metastatic lesions and underwent a triple- combination therapy with stereotactic ablative radiotherapy (SABR), granulocyte-macrophage col-ony-stimulating factor, and tislelizumab. Specifically, eight of these lesions received SABR treat-ment with a radiation dose of 50 Gy. Results: The therapy resulted in partial response after six months. The patient attained a progression-free survival period of 24 months. This case marks the first documented instance of effective application of triple-combination therapy in treating EC. Con-clusion: We opine that this therapy holds great promise as a second-line treatment for EC patients who have developed lung metastases. Notwithstanding the promising results, further exploration of this treatment avenue is warranted.

关 键 词：立体定向放射治疗 替雷利珠单抗 子宫内膜癌 肺转移 

分 类 号：R73[医药卫生—肿瘤]